 Breda, the Netherlands October 8 , 2021 argenx Euronext Nasdaq: ARGX, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancers, today announced the presentation of additional data from the Phase 3 ADAPT trial of efgartigimod for the treatment of generalized myasthenia gravis gMG. The data will be presented at two upcoming neuromuscular meetings: the American Association of Neuromuscular and Electrodiagnostic Medicine AANEM Annual Meeting on October 13-16, 2021 in Aurora, CO and the virtual Myasthenia Gravis Foundation of America Scientific Session MGFA on October 30, 2021. 